Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease

被引：6

作者：

Katagishi, Daiki ^{[1
]}

Yasuda, Daisuke ^{[1
]}

Takahashi, Kyoko ^{[2
]}

Nakamura, Shigeo ^{[2
]}

Mashino, Tadahiko ^{[1
]}

Ohe, Tomoyuki ^{[1
]}

机构：

[1] Keio Univ, Fac Pharm, Dept Pharmaceut Sci, 1-5-30 Shibakoen,Minato Ku, Tokyo, Japan

[2] Nippon Med Sch, Dept Chem, 1-7-1 Kyonan Cho,Musashino, Tokyo, Japan

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2023年 / 80卷

关键词：

Fullerene; COVID-19; SARS-CoV-2; Main protease; REVERSE TRANSCRIPTASE INHIBITION; C-60; POLYMERASE;

D O I：

10.1016/j.bmcl.2022.129121

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

COVID-19 is an ongoing worldwide pandemic. Even today, there is a need for the development of effective therapeutic agents. SARS-CoV-2 is known as the causative virus of COVID-19, and its main protease is one of the enzymes essential for its growth and is considered a drug discovery target. In this study, we evaluated the inhibitory activities of a variety of fullerene derivatives, including newly synthesized derivatives, against the main protease of SARS-CoV-2. As a result, the malonic acid-type fullerene derivatives showed the strongest inhibitory activity.

引用

页数：5

共 50 条

[21] A cyclic peptide inhibitor of the SARS-CoV-2 main protease
Kreutzer, Adam G.
Krumberger, Maj
Diessner, Elizabeth M.
Parrocha, Chelsea Marie T.
Morris, Michael A.
Guaglianone, Gretchen
Butts, Carter T.
Nowick, James S.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 221
[22] Inhibitors of SARS-CoV-2 main protease: Biological efficacy and toxicity aspects
Viskupicova, Jana
Rezbarikova, Petronela
Kovacikova, Lucia
Kandarova, Helena
Majekova, Magdalena
TOXICOLOGY IN VITRO, 2023, 92
[23] Computational study on peptidomimetic inhibitors against SARS-CoV-2 main protease
Somboon, Tuanjai
Mahalapbutr, Panupong
Sanachai, Kamonpan
Maitarad, Phornphimon
Lee, Vannajan Sanghiran
Hannongbua, Supot
Rungrotmongkol, Thanyada
JOURNAL OF MOLECULAR LIQUIDS, 2021, 322
[24] Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors
Fiorucci, Diego
Milletti, Eva
Orofino, Francesco
Brizzi, Antonella
Mugnaini, Claudia
Corelli, Federico
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2021, 39 (16) : 6242 - 6248
[25] Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2
Tripathi, Praveen Kumar
Upadhyay, Saurabh
Singh, Manju
Raghavendhar, Siva
Bhardwaj, Mohit
Sharma, Pradeep
Patel, Ashok Kumar
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2020, 164 : 2622 - 2631
[26] Drug development targeting SARS-CoV-2 main protease
Bulut, Haydar
GLOBAL HEALTH & MEDICINE, 2022, 4 (06): : 296 - 300
[27] Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors
Bhardwaj, Vijay Kumar
Singh, Rahul
Sharma, Jatin
Rajendran, Vidya
Purohit, Rituraj
Kumar, Sanjay
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2021, 39 (10) : 3449 - 3458
[28] Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
Mengist, Hylemariam Mihiretie
Mekonnen, Daniel
Mohammed, Ahmed
Shi, Ronghua
Jin, Tengchuan
FRONTIERS IN PHARMACOLOGY, 2021, 11
[29] A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals
Alugubelli, Yugendar R.
Geng, Zhi Zachary
Yang, Kai S.
Shaabani, Namir
Khatua, Kaustav
Ma, Xinyu R.
Vatansever, Erol C.
Cho, Chia-Chuan
Ma, Yuying
Xiao, Jing
Blankenship, Lauren R.
Yu, Ge
Sankaran, Banumathi
Li, Pingwei
Allen, Robert
Ji, Henry
Xu, Shiqing
Liu, Wenshe Ray
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 240
[30] Molecular Docking of Novel 5-O-benzoylpinostrobin Derivatives as SARS-CoV-2 Main Protease Inhibitors
Pratama, Mohammad Rizki Fadhil
Poerwono, Hadi
Siswodihardjo, Siswandono
PHARMACEUTICAL SCIENCES, 2020, 26 : S63 - S77

← 1 2 3 4 5 →